Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics' Q2 Loss Rises in Advance of Commercialization Efforts

NEW YORK (GenomeWeb News) - Rosetta Genomics today reported that its second-quarter net loss rose around 61 percent as the firm received approval from the State of New York to offer its first miRNA-based diagnostic test for differentiating squamous from non-squamous non-small cell lung cancer.
The Rehovot, Israel-based company had no revenues for the three-month period ended June 30. It expects to launch the first test later this year through Columbia University Medical Center’s High Complexity Molecular Pathology Laboratory.
Rosetta’s net loss for the second quarter was $3.7 million, or $.31 per share, compared to a net loss of $2.3 million, or $.19 per share, for the second quarter of 2007.
The firm’s R&D costs increased 23 percent to $2.2 million from $1.7 million year over year, and its marketing and business development expenses inched up to $434,000 from $412,000. Its general and administrative costs rose 51 percent to $896,000 from $595,000 for the second quarter of 2007.
Rosetta finished the quarter with $12.1 million in cash and cash equivalents.
Rosetta President and CEO Amir Avniel noted that the firm expects to submit two additional tests — one for differentiating mesothelioma from adenocarcinomas in the lung and one for identifying the primary origin of a metastasis — for regulatory approval in “the coming months.” He also said that the firm would soon begin development of tests at its newly acquired CLIA lab.
Rosetta said last month that it would acquire Parkway Clinical Laboratories, a privately held CLIA-certified lab, for $2.9 million and an additional $300,000 if certain milestones are met.
The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.